Skip to main content
. 2013 Apr 28;2013:658371. doi: 10.1155/2013/658371

Table 3.

Univariate analysis overall survival and progression-free survival.

Variables Overall survival Progression-free survival
HR 95% CI P HR 95% CI P
At diagnosis
Age > 45 years 1.01 0.34–2.42 0.9 0.87 0.44–1.98 0.7
Female versus male 0.34
0.15–0.72
<0.004
0.62 0.34–1.10 0.1
Albumin ≥ 4 0.30
0.14–0.61
<0.0009
0.38 0.21–0.69 <0.001
ALC ≥ 0.6 cells/µL 0.12
0.06–0.24
<0.0001
0.25 0.14–0.45 <0.0001
Mediastinal ≥ 10 cm 2.06 0.93–4.26 0.07 1.87 0.93–3.51 0.08
Hemoglobin < 10.5 g/dL 3.31 1.61–6.72 <0.002 2.16 1.15–3.89 <0.02
Stage 4 1.14 0.52–2.86 0.3 1.37 0.71–2.51 0.3
WBC > 15 cells/µL 4.68 2.24–9.49 <0.0001 3.18 1.64–5.84 <0.001
IPS ≥ 3 4.20 2.07–8.66 <0.0001 2.89 1.59–5.14 <0.0006
Limited versus advanced stage 0.92 0.45–1.86 0.8 0.73 0.40–1.30 0.3
Infused CD34+ stem cells 0.83 0.65–1.04 0.1 0.96 0.80–1.12 0.6
Pretransplant response (CR versus PR) 0.54 0.16–1.39 0.2 0.49 0.19–1.07 0.08
At day 15 post-APBHSCT
ALC ≥ 0.5 cells/µL 0.12 0.05–0.25 <0.0001 0.21 0.11–0.37 <0.0001
At day 100 post-APBHSCT
Age, continuous 0.99 0.97–1.03 0.9 0.95 0.87–1.11 0.5
ALC, continuous 0.33 0.16–0.61 <0.0001 0.48 0.29–0.75 <0.0006
ALC ≥ 0.8 cells/µL 0.28 0.15–0.59 <0.0001 0.28 0.16–0.50 <0.0001
AMC, continuous 2.16 1.46–2.92 <0.0001 1.80 1.24–2.40 <0.0001
AMC ≥ 0.63 cells/µL 7.55 3.64–15.93 <0.0001 3.88 2.12–7.06 <0.0001
ALC/AMC, continuous 0.03 0.01–0.10 <0.0001 0.49 0.37–0.63 <0.0001
ALC/AMC ≥ 1.3 0.07 0.03–0.15 <0.0001 0.18 0.10–0.32 <0.0001
ANC, continuous 1.10 0.86–1.37 0.5 1.01 0.81–1.22 0.9
Hgb, continuous 0.93 0.76–1.13 0.5 0.96 0.82–1.13 0.7
WBC, continuous 1.06 0.89–1.22 0.5 1.00 0.86–1.14 0.9
Plts, continuous 0.91 0.87–1.11 0.2 0.97 0.90–1.17 0.3

Abbreviations: ALC: absolute lymphocyte count; ANC: absolute neutrophil count; AMC: absolute monocyte count; CR: complete remission; IPS: international prognostic score; PR: partial response; Plts: platelets; WBC: white blood cell count.